AstraZeneca (STU:ZEGA) Short Interest


STU:ZEGA AstraZeneca PLC STU:ZEGA
87 GF Score
Price €78.00
GF Value €73.01
! 5 Warning Signs
View Full Analysis

What is AstraZeneca Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:ZEGA vs LLY, JNJ, ABBV: Short Interest Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Short Interest distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Short Interest falls into.


STU:ZEGA
87GF Score
AstraZeneca PLC STU:ZEGA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (STU:ZEGA) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued. The current stock price of €78.00 is trading 6.8% above its estimated GF Value™ of €73.01.

Key valuation signals for STU:ZEGA:

  • Short Interest:
  • GF Value™: €73.01 vs. price of €78.00 (6.8% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
87GF Score

Get the complete analysis for STU:ZEGA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€73.01
GF Value